Page 109 - 2019_04-Haematologica-web

Epigenetic matrix and targeted therapy of BPDCN
novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasmacy- toid dendritic cell neoplasm. Clin Cancer Res. 2011;17(19):6163-6173.
14. Jardin F, Ruminy P, Parmentier F, et al. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neo- plasm. Br J Haematol. 2011;153(3):413-416.
15. Lucioni M, Novara F, Fiandrino G, et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood. 2011;118(17):4591-4594.
16. Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88(12):1055-1061.
17. Sapienza MR, Fuligni F, Agostinelli C, et al. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pat- tern and suggests selective sensitivity to NF- kB pathway inhibition. Leukemia. 2014;28(8):1606-1616.
18. Philippe L, Ceroi A, Bole-Richard E, et al. Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neo- plasm. Haematologica. 2017;102(11):1861- 1868.
19. Menezes J, Acquadro F, Wiseman M, et al. Exome sequencing reveals novel and recur- rent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28(4):823-829.
20. Stenzinger A, Endris V, Pfarr N, et al. Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid den- dritic cell neoplasm. Oncotarget. 2014;5(15): 6404-6413.
21. Emadali A, Hoghoughi N, Duley S, et al. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neo- plasms. Blood. 2016;127(24):3040-3053.
22. Montero J, Stephansky J, Cai T, et al. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017;7(2):156- 164.
23. Ceroi A, Masson D, Roggy A, et al. LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis. Blood. 2016;128(23):2694-2707.
24. Ceribelli M, Hou ZE, Kelly PN, et al. A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid
Dendritic Cell Neoplasm. Cancer Cell.
2016;30(5):764-778.
25. Angelot-Delettre F, Roggy A, Frankel AE, et
al. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL- 401, an interleukin-3 receptor targeted bio- logic agent. Haematologica. 2015;100(2): 223-230.
26. Fanelli M, Amatori S, Barozzi I, et al. Pathology tissue-chromatin immunoprecipi- tation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples. Proc Natl Acad Sci U S A. 2010;107(50):21535-21540.
27. Maeda T, Murata K, Fukushima T, et al. A novel plasmacytoid dendritic cell line, CAL- 1, established from a patient with blastic natural killer cell lymphoma. Int J Hematol. 2005;81(2):148-154.
28. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25-29.
29. Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012; 120(17):3397- 3406.
30. Guarini A, Marinelli M, Tavolaro S, et al. ATM gene alterations in chronic lymphocyt- ic leukemia patients induce a distinct gene expression profile and predict disease pro- gression. Haematologica. 2012;97(1):47-55.
31. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta- catenin signalling pathway in acute myeloid leukaemia. Oncogene. 2005; 24(14):2410- 2420.
32. Kuo YH, Zaidi SK, Gornostaeva S, Komori T, Stein GS, Castilla LH. Runx2 induces acute myeloid leukemia in cooperation with Cbfbeta-SMMHC in mice. Blood. 2009;113(14):3323-3332.
33. Togami K, Madan V, Li J, et al. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Harbors Frequent Splicesosome Mutations That Cause Aberrant RNA Splicing Affecting Genes Critical in pDC Differentiation and Function. Blood. 2016; 128(22):738.
34. Scibetta AG, Santangelo S, Coleman J, et al. Functional analysis of the transcription repressor PLU-1/JARID1B. Mol Cell Biol. 2007;27(20):7220-7235.
35. Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S. Human SWI/SNF-associ- ated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol. 2004;24(21):9630-9645.
36. Missiaglia E, Donadelli M, Palmieri M,
Crnogorac-Jurcevic T, Scarpa A, Lemoine NR. Growth delay of human pancreatic can- cer cells by methylase inhibitor 5-aza-2'- deoxycytidine treatment is associated with activation of the interferon signalling path- way. Oncogene. 2005;24(1):199-211.
37. Lee KH, Park JW, Sung HS, et al. PHF2 his- tone demethylase acts as a tumor suppressor in association with p53 in cancer. Oncogene. 2015;34(22):2897-2909.
38. Subtil-Rodriguez A, Vazquez-Chavez E, Ceballos-Chavez M, et al. The chromatin remodeller CHD8 is required for E2F-depen- dent transcription activation of S-phase genes. Nucleic Acids Res. 2014;42(4):2185- 2196.
39. Rotili D, Mai A. Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes Cancer. 2011;2(6): 663-679.
40. Jin Y, Zhou J, Xu F, et al. Targeting methyl- transferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J Clin Invest. 2016;126(10):3961-3980.
41. Yamane K, Tateishi K, Klose RJ, et al. PLU-1 is an H3K4 demethylase involved in tran- scriptional repression and breast cancer cell proliferation. Mol Cell. 2007;25(6):801-812.
42. Tang B, Qi G, Tang F, et al. JARID1B pro- motes metastasis and epithelial-mesenchy- mal transition via PTEN/AKT signaling in hepatocellular carcinoma cells. Oncotarget. 2015;6(14):12723-12739.
43. Zhang T, Cooper S, Brockdorff N. The inter- play of histone modifications - writers that read. EMBO Rep. 2015;16(11):1467-1481.
44. Quintas-Cardama A, Santos FP, Garcia- Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol. 2010;7(8):433-444.
45. Jabbour E, Short NJ, Montalban-Bravo G, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower- risk MDS and MDS/MPN. Blood. 2017;130(13):1514-1522.
46. Kalac M, Scotto L, Marchi E, et al. HDAC inhibitors and decitabine are highly syner- gistic and associated with unique gene- expression and epigenetic profiles in mod- els of DLBCL. Blood. 2011;118(20):5506- 5516.
47. Laribi K, Denizon N, Ghnaya H, et al. Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacy- tidine. Eur J Haematol. 2014;93(1):81-85.
48. Khwaja R, Daly A, Wong M, Mahe E, Cerquozzi S, Owen C. Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases. Leuk Lymphoma. 2016;57(11):2720-2722.
haematologica | 2019; 104(4)
737